产品
编 号：F012220
分子式：C38H51N3O12S2
分子量：805.95
分子式：C38H51N3O12S2
分子量：805.95
产品类型
规格
价格
是否有货
结构图
CAS No: 1025216-57-2
产品详情
生物活性：
Volixibat (SHP626) is a highly selective, minimally absorbed, and competitive apical sodium-dependent bile acid transporter (ASBT) inhibitor. Volixibat has potential for treatment for non-alcoholic steatohepatitis (NASH).
体内研究：
Volixibat (SHP626) (5-30 mg/kg; food intake; daily for 24 weeks) improves metabolic aspects and components of non-alcoholic steatohepatitis in Ldlr-/-.Leiden mice.Animal Model:Male Ldlr-/-.Leiden mice (high-fat diet, HFD)
Dosage:5, 15, or 30 mg/kg
Administration:Food intake; daily for 24 weeks
Result:Significantly increased the total amount of bile acid in feces. Significantly attenuated the HFD-induced increase in hepatocyte hypertrophy, hepatic triglyceride and cholesteryl ester levels, and mesenteric white adipose tissue deposition at the highest dose. Non-alcoholic fatty liver disease activity score (NAS) was significantly lower in volixibat-treated mice than in the HFD controls.
Volixibat (SHP626) is a highly selective, minimally absorbed, and competitive apical sodium-dependent bile acid transporter (ASBT) inhibitor. Volixibat has potential for treatment for non-alcoholic steatohepatitis (NASH).
体内研究：
Volixibat (SHP626) (5-30 mg/kg; food intake; daily for 24 weeks) improves metabolic aspects and components of non-alcoholic steatohepatitis in Ldlr-/-.Leiden mice.Animal Model:Male Ldlr-/-.Leiden mice (high-fat diet, HFD)
Dosage:5, 15, or 30 mg/kg
Administration:Food intake; daily for 24 weeks
Result:Significantly increased the total amount of bile acid in feces. Significantly attenuated the HFD-induced increase in hepatocyte hypertrophy, hepatic triglyceride and cholesteryl ester levels, and mesenteric white adipose tissue deposition at the highest dose. Non-alcoholic fatty liver disease activity score (NAS) was significantly lower in volixibat-treated mice than in the HFD controls.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备